| 4.44 -0.13 (-2.84%) | 05-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.72 | 1-year : | 6.49 |
| Resists | First : | 4.89 | Second : | 5.55 |
| Pivot price | 4.23 |
|||
| Supports | First : | 3.82 | Second : | 3.18 |
| MAs | MA(5) : | 4.41 |
MA(20) : | 4.21  |
| MA(100) : | 6.26 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 57.6 |
D(3) : | 53 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 20.7 | Low : | 2.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SGMT ] has closed below upper band by 23.7%. Bollinger Bands are 84.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.72 - 4.75 | 4.75 - 4.77 |
| Low: | 4.31 - 4.33 | 4.33 - 4.35 |
| Close: | 4.4 - 4.44 | 4.44 - 4.47 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Mon, 06 May 2024
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer - GlobeNewswire
Mon, 06 May 2024
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at HC Wainwright - Defense World
Mon, 06 May 2024
Sagimet Biosciences Inc. Expected to Post Q1 2024 Earnings of ($0.41) Per Share (NASDAQ:SGMT) - MarketBeat
Sat, 04 May 2024
Federated Hermes Inc. Has $527000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Fri, 26 Apr 2024
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Opportunity (SGMT) - Seeking Alpha
Thu, 28 Mar 2024
Sagimet Biosciences CEO David Happel buys $63730 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.759e+007 (%) |
| Held by Institutions | 14.3 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 537 % |
| Return on Equity (ttm) | -29.7 % |
| Qtrly Rev. Growth | 2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 67.44 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.07e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|